{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=20", "query": { "condition": "Head Neck Cancer Squamous Cell Metastatic", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 598, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T17:09:56.040Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Enzyme Inhibitor Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-10-03", "completion_date": "2022-10-30", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229278" }, { "nct_id": "NCT05551117", "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostatic Cancer", "Androgen-Independent Prostatic Cancer", "Androgen-Insensitive Prostatic Cancer", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Anal Cancer", "Anal Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Squamous Cell Carcinoma", "Malignant Melanoma", "Melanoma", "Non-small Cell Lung Cancer", "Non-small Cell Carcinoma", "Small-cell Lung Cancer", "Small Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine 2.0 mg (Arm A)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine 2.7 mg (Arm B)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2023-06-13", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 14, "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05551117" }, { "nct_id": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HNSCC", "Lip SCC", "Oral Cavity Cancer", "Oropharynx Cancer", "Larynx Cancer", "Hypopharynx Cancer", "Nasopharynx Cancer", "Sinonasal Carcinoma", "Cutaneous Squamous Cell Carcinoma", "Head and Neck Neoplasms", "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab, Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2017-03-28", "completion_date": "2025-09-11", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03082534" }, { "nct_id": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "TTX-080", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tizona Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2020-07-14", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 41, "location_summary": "Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04485013" }, { "nct_id": "NCT03854227", "title": "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "PF-06939999 dose escalation", "type": "DRUG" }, { "name": "PF-06939999 monotherapy", "type": "DRUG" }, { "name": "PF-06939999 in combination with docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-03-14", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03854227" }, { "nct_id": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Squamous Cell Carcinoma of Head and Neck", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Sarcoma", "Endometrial Cancer", "Melanoma", "Castration Resistant Prostatic Cancer", "Cervical Cancer", "Colorectal Cancer", "Gastric Cancer", "Gastro-esophageal Cancer", "Pancreas Cancer", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Platinum-resistant Ovarian Cancer", "Breast Cancer", "Ovarian Cancer", "Esophageal Squamous Cell Cancer (SCC)" ], "interventions": [ { "name": "MGC026 Dose Escalation", "type": "BIOLOGICAL" }, { "name": "MGC026 Dose for Expansion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-03-06", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 7, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06242470" }, { "nct_id": "NCT06332755", "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer(NSCLC)", "Head and Neck Squamous Cell Carcinoma(HNSCC)", "Renal Cell Carcinoma(RCC)", "Urothelial Carcinoma", "Malignant Melanoma" ], "interventions": [ { "name": "Phase 1a: LB-LR1109", "type": "DRUG" }, { "name": "Phase 1b: LB-LR1109 and Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LG Chem", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2024-06-05", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06332755" }, { "nct_id": "NCT04260126", "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Cancer", "Recurrent Head and Neck Cancer", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Pembrolizumab (KEYTRUDA®) and PDS0101", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "PDS Biotechnology Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2021-03-29", "completion_date": "2025-05-14", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 18, "location_summary": "Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04260126" }, { "nct_id": "NCT04862650", "title": "Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Unknown Primary", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVC Hypopharyngeal Carcinoma AJCC v8", "Stage IVC Laryngeal Cancer AJCC v8", "Stage IVC Lip and Oral Cavity Cancer AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Marcelo Bonomi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2021-11-30", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04862650" }, { "nct_id": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Non-small Cell Lung Cancer, Squamous", "Non-small Cell Lung Cancer, Non-squamous", "Head and Neck Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Prostate Cancer", "Melanoma" ], "interventions": [ { "name": "ladiratuzumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2019-10-09", "completion_date": "2023-11-28", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-26T17:09:56.040Z", "location_count": 27, "location_summary": "Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04032704" } ] }